Our top pick for
Colony Capital Inc is a reit-diversified business based in the US. Colony Capital shares (CLNY) are listed on the NYSE and all prices are listed in US Dollars. Colony Capital employs 300 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.87|
|52-week range||$6.61 - $8.30|
|50-day moving average||$7.51|
|200-day moving average||$6.28|
|Wall St. target price||$8.65|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-5.62|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-20)||N/A|
|1 month (2022-05-28)||N/A|
|3 months (2022-03-28)||N/A|
|6 months (2021-12-28)||N/A|
|1 year (2021-07-01)||-13.69%|
|2 years (2020-07-01)||175.90%|
|3 years (2019-07-01)||37.13%|
|5 years (2017-06-30)||14.09|
Valuing Colony Capital stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Colony Capital's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Colony Capital's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $475.6 million.
The EBITDA is a measure of a Colony Capital's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.4 billion|
|Gross profit TTM||$849.6 million|
|Return on assets TTM||-0.19%|
|Return on equity TTM||-33.2%|
|Market capitalisation||$4.1 billion|
TTM: trailing 12 months
We're not expecting Colony Capital to pay a dividend over the next 12 months.
Colony Capital's shares were split on 10 January 2017.
Over the last 12 months, Colony Capital's shares have ranged in value from as little as $6.61 up to $8.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Colony Capital's is 2.0039. This would suggest that Colony Capital's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Colony Capital, Inc. (NYSE: CLNY) is a leading global investment firm with a heritage of identifying and capitalizing on key secular trends in real estate. The Company manages an approximately $47 billion portfolio of real assets on behalf of its shareholders and limited partners, including over $23 billion in digital real estate investments through Digital Colony, its digital infrastructure platform. Colony Capital, structured as a REIT, is headquartered in Los Angeles with key offices in Boca Raton, New York, and London, and has over 350 employees across 20 locations in 11 countries. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.